Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B

Jun Liu; Patrick Budylowski; Reuben Samson; Bryan D. Griffin; Giorgi Babuadze; Bhavisha Rathod; Karen Colwill; Jumai A. Abioye; Jordan A. Schwartz; Ryan Law; Lily Yip; Sang Kyun Ahn; Serena Chau; Maedeh Naghibosadat; Yuko Arita; Queenie Hu; Feng Yun Yue; Arinjay Banerjee; W. Rod Hardy; Karen Mossman; Samira Mubareka; Robert A. Kozak; Michael S. Pollanen; Natalia Martin Orozco; Anne Claude Gingras; Eric G. Marcusson; Mario A. Ostrowski

doi:10.1126/sciadv.abj9815

Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B

Jun Liu, Patrick Budylowski, Reuben Samson, Bryan D. Griffin, Giorgi Babuadze, Bhavisha Rathod, Karen Colwill, Jumai A. Abioye, Jordan A. Schwartz, Ryan Law, Lily Yip, Sang Kyun Ahn, Serena Chau, Maedeh Naghibosadat, Yuko Arita, Queenie Hu, Feng Yun Yue, Arinjay Banerjee, W. Rod Hardy, Karen MossmanSamira Mubareka, Robert A. Kozak, Michael S. Pollanen, Natalia Martin Orozco, Anne Claude Gingras, Eric G. Marcusson, Mario A. Ostrowski

Research output: Contribution to journal › Article › peer-review

Abstract

Safe and effective vaccines are needed to end the COVID-19 pandemic. Here, we report the preclinical development of a lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccine, PTX-COVID19-B. PTX-COVID19-B was chosen among three candidates after the initial mouse vaccination results showed that it elicited the strongest neutralizing antibody response against SARS-CoV-2. Further tests in mice and hamsters indicated that PTX-COVID19-B induced robust humoral and cellular immune responses and completely protected the vaccinated animals from SARS-CoV-2 infection in the lung. Studies in hamsters also showed that PTX-COVID19-B protected the upper respiratory tract from SARS-CoV-2 infection. Mouse immune sera elicited by PTX-COVID19-B vaccination were able to neutralize SARS-CoV-2 variants of concern, including the Alpha, Beta, Gamma, and Delta lineages. No adverse effects were induced by PTX-COVID19-B in either mice or hamsters. Based on these results, PTX-COVID19-B was authorized by Health Canada to enter clinical trials in December 2020 with a phase 2 clinical trial ongoing.

Original language	English (US)
Article number	eabj9815
Journal	Science Advances
Volume	8
Issue number	3
DOIs	https://doi.org/10.1126/sciadv.abj9815
State	Published - Jan 2022
Externally published	Yes

ASJC Scopus subject areas

General

Access to Document

10.1126/sciadv.abj9815

Cite this

Liu, J., Budylowski, P., Samson, R., Griffin, B. D., Babuadze, G., Rathod, B., Colwill, K., Abioye, J. A., Schwartz, J. A., Law, R., Yip, L., Ahn, S. K., Chau, S., Naghibosadat, M., Arita, Y., Hu, Q., Yue, F. Y., Banerjee, A., Hardy, W. R., ... Ostrowski, M. A. (2022). Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B. Science Advances, 8(3), Article eabj9815. https://doi.org/10.1126/sciadv.abj9815

Liu, J, Budylowski, P, Samson, R, Griffin, BD, Babuadze, G, Rathod, B, Colwill, K, Abioye, JA, Schwartz, JA, Law, R, Yip, L, Ahn, SK, Chau, S, Naghibosadat, M, Arita, Y, Hu, Q, Yue, FY, Banerjee, A, Hardy, WR, Mossman, K, Mubareka, S, Kozak, RA, Pollanen, MS, Orozco, NM, Gingras, AC, Marcusson, EG & Ostrowski, MA 2022, 'Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B', Science Advances, vol. 8, no. 3, eabj9815. https://doi.org/10.1126/sciadv.abj9815

@article{930882062975401eba651c5ff3565027,

title = "Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B",

abstract = "Safe and effective vaccines are needed to end the COVID-19 pandemic. Here, we report the preclinical development of a lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccine, PTX-COVID19-B. PTX-COVID19-B was chosen among three candidates after the initial mouse vaccination results showed that it elicited the strongest neutralizing antibody response against SARS-CoV-2. Further tests in mice and hamsters indicated that PTX-COVID19-B induced robust humoral and cellular immune responses and completely protected the vaccinated animals from SARS-CoV-2 infection in the lung. Studies in hamsters also showed that PTX-COVID19-B protected the upper respiratory tract from SARS-CoV-2 infection. Mouse immune sera elicited by PTX-COVID19-B vaccination were able to neutralize SARS-CoV-2 variants of concern, including the Alpha, Beta, Gamma, and Delta lineages. No adverse effects were induced by PTX-COVID19-B in either mice or hamsters. Based on these results, PTX-COVID19-B was authorized by Health Canada to enter clinical trials in December 2020 with a phase 2 clinical trial ongoing.",

author = "Jun Liu and Patrick Budylowski and Reuben Samson and Griffin, {Bryan D.} and Giorgi Babuadze and Bhavisha Rathod and Karen Colwill and Abioye, {Jumai A.} and Schwartz, {Jordan A.} and Ryan Law and Lily Yip and Ahn, {Sang Kyun} and Serena Chau and Maedeh Naghibosadat and Yuko Arita and Queenie Hu and Yue, {Feng Yun} and Arinjay Banerjee and Hardy, {W. Rod} and Karen Mossman and Samira Mubareka and Kozak, {Robert A.} and Pollanen, {Michael S.} and Orozco, {Natalia Martin} and Gingras, {Anne Claude} and Marcusson, {Eric G.} and Ostrowski, {Mario A.}",

note = "Publisher Copyright: Copyright {\textcopyright} 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).",

year = "2022",

month = jan,

doi = "10.1126/sciadv.abj9815",

language = "English (US)",

volume = "8",

journal = "Science Advances",

issn = "2375-2548",

publisher = "American Association for the Advancement of Science",

number = "3",

}

TY - JOUR

T1 - Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B

AU - Liu, Jun

AU - Budylowski, Patrick

AU - Samson, Reuben

AU - Griffin, Bryan D.

AU - Babuadze, Giorgi

AU - Rathod, Bhavisha

AU - Colwill, Karen

AU - Abioye, Jumai A.

AU - Schwartz, Jordan A.

AU - Law, Ryan

AU - Yip, Lily

AU - Ahn, Sang Kyun

AU - Chau, Serena

AU - Naghibosadat, Maedeh

AU - Arita, Yuko

AU - Hu, Queenie

AU - Yue, Feng Yun

AU - Banerjee, Arinjay

AU - Hardy, W. Rod

AU - Mossman, Karen

AU - Mubareka, Samira

AU - Kozak, Robert A.

AU - Pollanen, Michael S.

AU - Orozco, Natalia Martin

AU - Gingras, Anne Claude

AU - Marcusson, Eric G.

AU - Ostrowski, Mario A.

N1 - Publisher Copyright: Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).

PY - 2022/1

Y1 - 2022/1

N2 - Safe and effective vaccines are needed to end the COVID-19 pandemic. Here, we report the preclinical development of a lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccine, PTX-COVID19-B. PTX-COVID19-B was chosen among three candidates after the initial mouse vaccination results showed that it elicited the strongest neutralizing antibody response against SARS-CoV-2. Further tests in mice and hamsters indicated that PTX-COVID19-B induced robust humoral and cellular immune responses and completely protected the vaccinated animals from SARS-CoV-2 infection in the lung. Studies in hamsters also showed that PTX-COVID19-B protected the upper respiratory tract from SARS-CoV-2 infection. Mouse immune sera elicited by PTX-COVID19-B vaccination were able to neutralize SARS-CoV-2 variants of concern, including the Alpha, Beta, Gamma, and Delta lineages. No adverse effects were induced by PTX-COVID19-B in either mice or hamsters. Based on these results, PTX-COVID19-B was authorized by Health Canada to enter clinical trials in December 2020 with a phase 2 clinical trial ongoing.

AB - Safe and effective vaccines are needed to end the COVID-19 pandemic. Here, we report the preclinical development of a lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccine, PTX-COVID19-B. PTX-COVID19-B was chosen among three candidates after the initial mouse vaccination results showed that it elicited the strongest neutralizing antibody response against SARS-CoV-2. Further tests in mice and hamsters indicated that PTX-COVID19-B induced robust humoral and cellular immune responses and completely protected the vaccinated animals from SARS-CoV-2 infection in the lung. Studies in hamsters also showed that PTX-COVID19-B protected the upper respiratory tract from SARS-CoV-2 infection. Mouse immune sera elicited by PTX-COVID19-B vaccination were able to neutralize SARS-CoV-2 variants of concern, including the Alpha, Beta, Gamma, and Delta lineages. No adverse effects were induced by PTX-COVID19-B in either mice or hamsters. Based on these results, PTX-COVID19-B was authorized by Health Canada to enter clinical trials in December 2020 with a phase 2 clinical trial ongoing.

UR - http://www.scopus.com/inward/record.url?scp=85123273313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123273313&partnerID=8YFLogxK

U2 - 10.1126/sciadv.abj9815

DO - 10.1126/sciadv.abj9815

M3 - Article

C2 - 35044832

AN - SCOPUS:85123273313

SN - 2375-2548

VL - 8

JO - Science Advances

JF - Science Advances

IS - 3

M1 - eabj9815

ER -

Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this